

RPPB2678

Product Information Protein Information

Product SKU:

RPPB2678

Accession:

P35968

Host:

Insect Cells.

Protein description:

Soluble VEGFR2 Fc Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a disulfide-linked homodimeric, glycosylated, polypeptide containing 968 amino acids and having a molecular mass of 145 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding. The sKDR Fc Chimera is purified by proprietary chromatographic techniques.

Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Synonyms:

KDR D1-7, sKDR D1-7, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2.

Formulation:

KDR fusion protein was lyophilized from a concentrated (1mg/ml) sterile solution containing 1xPBS pH-7.2.

Purity:

Greater than 90.0% as determined by SDS-PAGE.

Solubility:

It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 50 µg/ml, which can then be further diluted to other aqueous solutions.

Stability:

Lyophilized VEGFR-2 Fc/Chimera protein although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Amino Acid Sequence:

ASVGLPSVSL DLPRLSIQKD ILTIKANTTL QITCRGQRDL DWLWPNNQSG SEQRVEVTEC SDGLFCKTLT
IPKVGINDTG AYKCFYRETD LASVIYVVYQ DYRSPFIASV SDQHGVVYIT ENKNKTVVIP CLGSISNLNV
SLCARYPEKR FVPDGNRISW DSKKGFTIPS YMISYAGMVF CEAKINDESY QSIMYIVVVV GYRIYDVVLS
PSHGIELSVG EKLVLNCTAR TELNVGIDFN WEYPSSKHQH KKLVNRLDKT QSGSEMKKFL STLTIDGVTR
SDQGLYTCAA SSGLMTKKNS TFVRVHEKPF VAFSGMESL VEATVGERVR IPAKYLGYPY PEIKWYKNGI
PLESNHTIKA GHVLTIMEVS ERDTGNYTVI LTNPISKEKQ SHVVSLLVVV PPOIGEKSLI SPVDSYQYGT
TQTLTCTVYA IPPPHHHHWY WQLEEECANE PSQAVSVTNP YPCEEWRSVE DFQGGNKIEV NKNQFALIEG
KNKTVSTLVI QAANVSALYK CEAVNKVGRG ERVISFHVTR GPEITLQPDQ QPTEQESVSL WCTADRSTFE
NLTWYKLGPO PLPIHVGELP TPVCKNLDL WKLNATMFSN STNDILIMEL KNASLQDQGD YVCLAQDRKT
KKRHCVVRQL TVLERVAPTI TGNLENQTTT IGESIEVSCT ASGNPPPQIM WFKDNETLVE DSGIVLKDGN

RNLTIRRVRK EDEGLYTCQA CSVLGCAKVE AFFIEGANA SDKTHTCPPC PAPELLGGPS VFLFPPKPKD
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY
KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN
NYKTTTPMLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK.

Biological Activity:

The activity of sVEGFR2/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.